Biomarkers in Oncology | Access & Reimbursment | US | NSCLC, Bladder Cancer, and Gastric / GEJ Adenocarcinoma | 2021
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is playing an increasingly important role in indications such as gastric and gastroesophageal junction (GEJ) adenocarcinoma. Although biomarker-associated therapies offer the advantage of selecting the patients most likely to respond to treatment, these therapies are premium-priced and often subject to payer restrictions and cost-containment strategies.
QUESTIONS ANSWERED
· What factors largely influence payers’ reimbursement decisions for biomarker-driven therapies in NSCLC, bladder cancer, and gastric and GEJ adenocarcinoma? What restrictions do they impose?
· Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?
· What impact do reimbursement and cost have in oncologists’ decisions to prescribe biomarker-driven therapies?
· What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?
· What factors influence reimbursement and access of companion biomarker tests?
GEOGRAPHY: United States.
PRIMARY RESEARCH: Survey of 100 U.S. medical oncologists and 30 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).
KEY DRUGS COVERED:
Tagrisso, Tarceva, Gilotrif, Iressa, Vizimpro, Rybrevant, Lumakras, Tabrecta, Tepmetko, Retevmo, Gavreto, Keytruda, Tecentriq, Balversa, Opdivo, and Enhertu
CONTENT HIGHLIGHTS:
- Reimbursement and contracting
- Access and prescribing
- Opportunities and challenges for emerging therapies
- Disease-specific special topic
